US, Indian biotech firms find common ground on key issues at BIO event
date:Sep 14, 2012
fety and efficacy testing and approval process.

The participants agreed that they do not believe that the compulsory licensing of innovative products or technology generally is an effective means of promoting access or affordability of healthcare. Moreover, it undermines incentives for companies and individuals to innovate in India, since it creates uncertainty about receiving economic returns for their innovations, they said. Indiscriminate use of compulsory licenses would thus jeopardise Ind
3/9 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/07 07:31